Incyte (NASDAQ:INCY) reported encouraging 24-week interim findings from its Phase 3 STOP-HS clinical trial program, evaluating povorcitinib, an oral JAK1 inhibitor, in adults with moderate to severe hidradenitis suppurativa (HS).
The study revealed that patients treated with povorcitinib experienced clinically significant and meaningful improvements through Week 24. Almost 60% of participants in both povorcitinib groups achieved HiSCR50, a primary measure of treatment response.
Patients also noted reductions in skin pain, starting as early as Week 3 and persisting throughout the trial.
The drug’s safety profile remained consistent with previous reports, and both dosing regimens were generally well tolerated.
These interim results highlight the potential of povorcitinib as an effective option for patients suffering from this difficult-to-treat inflammatory skin disorder.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.